| Literature DB >> 31534784 |
Kerem Keserlioglu1, Halil Kilicoglu2, Gerben Ter Riet3,4.
Abstract
BACKGROUND: In their research reports, scientists are expected to discuss limitations that their studies have. Previous research showed that often, such discussion is absent. Also, many journals emphasize the importance of avoiding overstatement of claims. We wanted to see to what extent editorial handling and peer review affects self-acknowledgment of limitations and hedging of claims.Entities:
Keywords: Before-after study; Hedging; Linguistic spin; Peer review; Randomized trial; Scientific reporting; Study limitations; Transparency
Year: 2019 PMID: 31534784 PMCID: PMC6745784 DOI: 10.1186/s41073-019-0078-2
Source DB: PubMed Journal: Res Integr Peer Rev ISSN: 2058-8615
The results of the crude and adjusted analyses
| Manuscript | Publication | Crude difference or proportion‡ (95% CI) | Adjusted difference† (95% CI) | |
|---|---|---|---|---|
| Number of limitation-acknowledging sentences (mean, SD) | 2.48 (3.62) | 3.87 (4.34) | 1.39 (1.09–1.76) | 0.62 (− 0.23–1.48) |
| Number of papers with zero limitation-acknowledging sentences ( | 202/446 | 147/446 | ||
| Number of manuscripts with zero limitation-acknowledging sentences whose publication had at least one | 63/202 | 31.2 (25.2–37.9) | ||
| Number of manuscripts with at least one limitation-acknowledging sentence whose publication had none | 8/244 | 3.28 (1.67–6.34) | ||
| Unweighted hedges (%) | 2.06 (0.76) | 2.13 (0.74) | 0.07 (0.04–0.10) | 0.04 (− 0.05–0.14) |
| Unweighted hedges, limitation-acknowledging sentences excluded (%) | 2.01 (0.77) | 2.05 (0.76) | 0.04 (0.01–0.08) | 0.06 (− 0.03–0.16) |
| Weighted hedges (%) | 7.07 (2.91) | 7.30 (2.82) | 0.23 (0.10–0.36) | 0.09 (− 0.28–0.47) |
| Weighted hedges, limitation-acknowledging sentences excluded (%) | 6.92 (2.95) | 7.05 (2.89) | 0.13 (0.01–0.26) | 0.05 (− 0.32–0.43) |
N = 440 because we were unable to find the impact factor of BMC Dermatology (contributing six manuscript-publication pairs); hedges were counted (and weighted), divided by the total number of words in the discussion section and multiplied by 100
SD standard deviation
‡Crude difference estimated using a mixed regression model without covariables (N = 446)
†Adjusted for journal impact factor (continuous), editorial team size (continuous), and composition of authors in terms of English proficiency (three dummy variables)
Journal characteristics
| BMC ( | BMJ Open ( | |
|---|---|---|
| Journal characteristic | ||
| Peer review type | Open | Open |
| Acceptance rate (%, range) | 45–55 | 55 |
| Impact factor* | 2.10 (1.66, 2.29) | 2.56 |
| Size editorial team* | 8 (6, 16) | 84 |
| Days until publication* | 196 (141, 270) | 192 (149, 225) |
*median (interquartile range)
Fig. 1Changes in the number of limitation-acknowledging sentences between manuscripts and publications as a function of the number such sentences in the manuscript. Left panel: manuscript-publication pairs below the median split. Right panel: manuscript-publication pairs above the median split. The median split was calculated as the average of the number of limitation-acknowledging sentences in the manuscript (L) and in the publication (L): (L + L)/2. These averages were ranked and the median (value = 2; interquartile range 0–5) determined. The lines are fitted using fractional polynomials with 95% confidence intervals (Stata 13.1, twoway fpfitci command). Note that, in both panels, the changes tend to increase with decreasing numbers of limitation-acknowledging sentences in the manuscript. In particular, the effect of peer review and editorial handling is large in those manuscripts above the median split (right panel) with zero limitation-acknowledging sentences in the manuscript. The vertical line in the right panel is the line x = 1. Cluttering of data points was prevented by jittering them. Therefore, data points for x = 0 are not placed exactly above the tick mark for x = 0 but somewhat scattered to the left and right. The same holds for all data points and for the vertical placement of the points
Sensitivity analyses
| Manuscript | Publication | Crude difference‡ (95%CI) | Adjusted difference† (95%CI) | |
|---|---|---|---|---|
| Number of limitation-acknowledging sentences (mean, SD) | 2.61 (3.81) | 3.96 (4.51) | NA | 1.74 (0.21–3.28) |
| Unweighted hedges (%) | 2.06 (0.76) | 2.13 (0.74) | 0.06 (0.03–0.10) | − 0.01 (− 0.18–0.15) |
| Unweighted hedges, limitation-acknowledging sentences excluded (%) | 2.01 (0.77) | 2.05 (0.76) | 0.04 (0.01–0.08) | 0.06 (− 0.03–0.16) |
| Weighted hedges (%) | 7.07 (2.91) | 7.30 (2.82) | 0.20 (0.07–0.34) | 0.03 (− 0.62–0.26) |
| Weighted hedges, limitation-acknowledging sentences excluded (%) | 6.92 (2.95) | 7.05 (2.89) | 0.13 (0.01–0.26) | 0.08 (−0.58–0.74) |
Results obtained via the same calculations as in Table 2, but excluding BMJ Open and BMC Medicine whose editorial team sizes were extremely large compared to the other 26 journals, namely, 84 and 182, respectively. After omitting these two journals, the median team size was 8 (IQR interquartile range; IQR 6–14). N = 357 because we were unable to find the impact factor of BMC Dermatology (contributing six manuscript-publication pairs); hedges were counted (and weighted), divided by the total number of words in the discussion section and multiplied by 100. NA not available, since that model did not converge and no coefficients were calculated
SD standard deviation
‡Crude difference estimated using a mixed regression model without covariables (N = 363);
†Adjusted for journal impact factor (continuous), editorial team size (continuous) and composition of authors in terms of English proficiency (three dummy variables)
Examples of what seven major reporting guidelines state about the need to mention limitations
| Reporting guideline | Suggestions pertaining to self-acknowledgment of limitations |
|---|---|
| CONSORT | Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses; generalizability (external validity, applicability) of the trial findings; interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence |
| CONSORT 2010 statement: extension to randomized pilot and feasibility trials | Pilot trial limitations, addressing sources of potential bias and remaining uncertainty about feasibility; generalizability (applicability) of pilot trial methods and findings to future definitive trial and other studies; interpretation consistent with pilot trial objectives and findings, balancing potential benefits and harms, and considering other relevant evidence. Implications for progression from pilot to future definitive trial, including any proposed amendments |
| Reporting of stepped wedge cluster randomized trials | Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses; generalizability (external validity, applicability) of the trial findings. Generalizability to clusters or individual participants, or both (as relevant); interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence. |
| CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement | Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses; generalizability (external validity, applicability) of the trial findings; interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence |
| PRISMA Preferred Reporting Items for Systematic Reviews and Meta-Analyses | Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias); provide a general interpretation of the results in the context of other evidence, and implications for future research |
| The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement | Discuss limitations of the study, taking into account sources of potential bias or imprecision; discuss both direction and magnitude of any potential bias; interpretation gives a |
| TRIPOD: Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis | Discuss any limitations of the study (such as non-representative sample, few events per predictor, missing data); interpretation: for validation, discuss the results with reference to performance in the development data and any other validation data. Give an overall interpretation of the results, considering objectives, |
Text was abstracted via http://www.equator-network.org/reporting-guidelines/consort-cent/, which was accessed on 12 June 2019